Tirzepatide is a one-of-a-kind drug only meant for individuals who are overweight or obese, i.e., those with a BMI of 27 or more and have a weight-related condition, such as diabetes, or those with a BMI of 30 or more
The co-evolutionary perspective of the food-medicine continuum and wild gathered and cultivated vegetables
Risk of bias assessment for blinding of participants and personnel, incomplete outcome data, selective reporting, and overall risk of bias are for the primary outcome (change in HbA1c)
KLOW repair + recovery (higher BPC-157/TB-500 emphasis) GLOW collagen + longevity (higher GHK-Cu emphasis) In practice, both are used interchangeably for most recovery applications
Patients taking the drug with alcohol use disorder reported less urges to drink
Rare but serious risks include pancreatitis, gallbladder disease, and dehydration